Developing a great drug is hard enough, but developing an R&D
platform that reliably churns out new high-quality experimental
compounds is a rare feat in biotech. That Regeneron (NASDAQ: REGN )
has managed to create one of the strongest platforms in antibodies is
both a credit to its leadership and IP, as well as a strong generator of
long-term value for shareholders. Regeneron's shares do not look
particularly cheap today, but upside from products like Eylea and
alirocumab and de-risking of the pipeline give shareholders some reason
to stay engaged.
Read the full article at The Motley Fool:
Can Regeneron Keep Churning Out Blockbusters?
No comments:
Post a Comment